18 Years - VISION and IVY Networks, September 2023-January 2024. 

MMWR: Morbidity and Mortality Weekly Report. 2024

Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 

Clinical Infectious Diseases. 2024

Interim estimates of 2023-24 seasonal influenza vaccine effectiveness - United States. 

MMWR: Morbidity and Mortality Weekly Report. 2024

Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 

Influenza and other respiratory viruses. 2024

Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 

Clinical Infectious Diseases. 2024

A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. 

Vaccine. 2023

Active postlicensure safety surveillance for recombinant zoster vaccine using electronic health record data. 

American Journal of Epidemiology. 2023

Association between aluminum exposure from vaccines before age 24 months and persistent asthma at age 24 to 59 months. 

Academic Pediatrics. 2023

COVID-19 booster vaccination in early pregnancy and surveillance for spontaneous abortion. 

JAMA network open. 2023

COVID-19 vaccine safety surveillance in early pregnancy in the United States: design factors affecting the association between vaccine and spontaneous abortion. 

American Journal of Epidemiology. 2023

Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 

Pediatrics. 2023

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 

Vaccine. 2023

Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 

American Journal of Transplantation. 2023

Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 

JAMA network open. 2023

Impact of accounting for correlation between COVID-19 and influenza vaccination in a COVID-19 vaccine effectiveness evaluation using a test-negative design. 

Vaccine. 2023

Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic. 

Obstetrics and Gynecology. 2023

Influenza vaccination among pregnant women: self-report compared with vaccination data from electronic health records, 2018-2020 influenza seasons. 

Public Health Reports. 2023

Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 

Journal of Infectious Diseases. 2023

Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink. 

Vaccine. 2023

Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. 

Vaccine. 2023

Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. 

Vaccine. 2023

Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes. 

Vaccine. 2023

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 

Journal of Infectious Diseases. 2023

Association of the COVID-19 pandemic with routine childhood vaccination rates and proportion up to date with vaccinations across 8 US health systems in the Vaccine Safety Datalink. 

JAMA pediatrics. 2022

Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 

American Journal of Transplantation. 2022

Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 

JAMA network open. 2022

Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. 

JAMA network open. 2022

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 

Vaccine. 2022

Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 

Pediatrics. 2022

Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero. 

Pediatrics. 2022

Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 

MMWR: Morbidity and Mortality Weekly Report. 2022

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 

BMJ (Clinical research ed.). 2022

Association of inadvertent 9-valent human papillomavirus vaccine in pregnancy with spontaneous abortion and adverse birth outcomes. 

JAMA network open. 2021

COVID-19 vaccination coverage among insured persons aged ≥16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Developing algorithms for identifying major structural birth defects using automated electronic health data. 

Pharmacoepidemiology and Drug Safety. 2021

Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 

New England Journal of Medicine. 2021

Incidence of pediatric inflammatory bowel disease within the Vaccine Safety Datalink network and evaluation of association with rotavirus vaccination. 

Vaccine. 2021

Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June-August 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 

MMWR: Morbidity and Mortality Weekly Report. 2021

Surveillance for adverse events after COVID-19 mRNA vaccination. 

JAMA. 2021

Temporal trends in undervaccination: a population-based cohort study. 

American Journal of Preventive Medicine. 2021

The childhood vaccination schedule and the lack of association with type 1 diabetes. 

Pediatrics. 2021

Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. 

Therapeutic advances in drug safety. 2021

Association between rotavirus vaccination and type 1 diabetes in children. 

JAMA pediatrics. 2020

Evaluating the association of stillbirths after maternal vaccination in the Vaccine Safety Datalink. 

Obstetrics and Gynecology. 2020

SARS-CoV-2 infection among hospitalized pregnant women: reasons for admission and pregnancy characteristics - eight U.S. health care centers, March 1-May 30, 2020. 

MMWR: Morbidity and Mortality Weekly Report. 2020

Similar relative risks of seizures following measles containing vaccination in children born preterm compared to full-term without previous seizures or seizure-related disorders. 

Vaccine. 2019

Uptake and safety of hepatitis A vaccination during pregnancy: a Vaccine Safety Datalink study. 

Vaccine. 2019

Infant hospitalizations and mortality after maternal vaccination. 

Pediatrics. 2018

Risk of spontaneous abortion after inadvertent human papillomavirus vaccination in pregnancy. 

Obstetrics and Gynecology. 2018

Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. 

Pharmacoepidemiology and Drug Safety. 2018

The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: a Vaccine Safety Datalink study. 

Pharmacoepidemiology and Drug Safety. 2018

Uptake and safety of Hepatitis B vaccination during pregnancy: a Vaccine Safety Datalink study. 

Vaccine. 2018

Congenital microcephaly: case definition & guidelines for data collection, analysis, and presentation of safety data after maternal immunisation. 

Vaccine. 2017

Febrile seizure risk after vaccination in children one to five months of age. 

Pediatric Neurology. 2017

First trimester influenza vaccination and risks for major structural birth defects in offspring. 

Journal of Pediatrics. 2017

Identifying birth defects in automated data sources in the Vaccine Safety Datalink. 

Pharmacoepidemiology and Drug Safety. 2017

Maternal Tdap vaccination and risk of infant morbidity. 

Vaccine. 2017

Maternal and infant outcomes after human papillomavirus vaccination in the periconceptional period or during pregnancy. 

Obstetrics and Gynecology. 2017

Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. 

BMC Pulmonary Medicine. 2017

Febrile seizure risk after vaccination in children 6 to 23 months. 

Pediatrics. 2016

Influenza vaccination during pregnancy: influenza seasons 2002-2012, Vaccine Safety Datalink. 

American Journal of Preventive Medicine. 2016

Maternal Tdap vaccination: coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013. 

Vaccine. 2016

Risk of anaphylaxis after vaccination in children and adults. 

Journal of Allergy and Clinical Immunology. 2016

Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: caveats when conducting retrospective observational studies. 

American Journal of Epidemiology. 2016

Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. 

JAMA. 2015

Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. 

Vaccine. 2015

Safety of measles-containing vaccines in 1-year-old children. 

Pediatrics. 2015

Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. 

Obstetrics and Gynecology. 2015

Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. 

JAMA. 2014

Receipt of pertussis vaccine during pregnancy across 7 Vaccine Safety Datalink Sites. 

Preventive Medicine. 2014

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. 

Vaccine. 2014

Vaccinations given during pregnancy, 2002-2009: a descriptive study. 

American Journal of Preventive Medicine. 2014

Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. 

JAMA pediatrics. 2013

Measles-containing vaccines and febrile seizures in children age 4 to 6 years. 

Pediatrics. 2012

Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. 

Vaccine. 2011

Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. 

Archives of Pediatrics and Adolescent Medicine. 2011

Lack of association between acellular pertussis vaccine and seizures in early childhood. 

Pediatrics. 2010

Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. 

Pediatrics. 2010

Varicella vaccination and ischemic stroke in children: is there an association?. 

Pediatrics. 2009

The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety [review]. 

Vaccine. 2014

Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes [presentation]